The team at Ghobrial Labs set out to better understand the effectiveness rates of COVID vaccines in people with multiple myeloma and also its precursor conditions including SMM, smoldering WM, and MGUS. Findings indicate a that the antibody response may be more robust among the healthy controls than among those who have MM and even its lower-risk precursor conditions. People with MM and precursor conditions may be more likely to have a lower level of vaccine protection from SARS-CoV-2 than the general population.
Because so many people may be unaware that they have these precursor conditions, the study findings may be relevant to the broader population as well. Read the publication here, originally published in Cancer Cell, and we welcome your thoughts.